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Survey of congenital heart surgeons' preferences for antimicrobial prophylaxis for
pediatric cardiac surgery patients
Chad A. Knoderer, Emily M. Anderson, Emily M. Anderson
Patients with congenital heart defects are a unique population with generally immature immune
systems. Fragility in the postoperative period may contribute to surgical site infections (SSIs), a
life threatening complication for this population. The need for postoperative antimicrobial
prophylaxis for these patients is a standard of care that is indisputable. When choosing an
antimicrobial regimen for surgical prophylaxis, consideration should be given to balancing the
prevention of nosocomial infections, avoiding emergence of bacterial resistance, and minimizing
drug toxicities and cost.
Organizations including the American Society of Health-System Pharmacists (ASHP), the
Society of Thoracic Surgeons (STS), the Surgical Infection Prevention (SIP) project team, the
Centers for Medicare and Medicaid Services, and the U.S. Centers for Disease Control and
Prevention have developed guidelines for the selection, initiation, and duration of antibiotic use
in patients perioperatively (table).1-4 Only ASHP recommendations specifically address surgical
prophylaxis for children undergoing cardiac surgery, although not in extensive detail and with
much extrapolation of data from adult studies. (1)
In November 2006, we surveyed 95 surgeons from 56 domestic and 4 international institutions
who were all members of the Congenital Heart Surgeons' Society, and we asked them to evaluate
the range of practice regarding postoperative antibiotic prophylaxis for pediatric cardiac
surgeries. As expected, there was a wide variation of practice related to selection and duration of
prophylaxis. Twenty-three (24%) congenital heart surgeons responded from 16 domestic and 2
international programs, but only three of the surgeons were familiar with the SIP project.
Cefazolin was the most commonly chosen antibiotic for postoperative prophylaxis. Nine (60%)
of 15 surgeons who responded stated that antibiotic prophylaxis is limited to 24 to 48 hours after
surgery. This is consistent with ASHP, SIP, and STS recommendations. (1-3) However, a high
percentage (40%; 6 of 15) reported continuing prophylaxis until chest tubes and all invasive lines
(i.e., central intravenous, arterial, and intracardiac hemodynamic monitoring) were removed.
Data from a retrospective study by Maher et al. (5) might suggest that this practice may decrease
SSIs. However, a prospective study has demonstrated that prolonged antibiotic prophylaxis after
48 hours does not reduce SSIs but increases antimicrobial resistance. (6) The practice of
continuing prophylaxis for the duration of chest tube or invasive line placement has existed for
some time and is currently not endorsed by STS. (3, 7)
Antibiotic prophylaxis guidelines do not exist for procedures such as ventricular assist device
(VAD) placement, cardiac extracorporeal membrane oxygenation (ECMO), and delayed sternal
closure (DSC) cases. Infection-related morbidity and mortality in patients who receive these
procedures is of significant concern. Use of vancomycin-containing regimens (21/42 [50%]) and
regimens containing antimicrobials with broad gram-negative or anaerobic coverage (i.e.,
cefoxitin, ceftazidime, ceftriaxone, gentamicin, piperacillin) were commonly reported by
surgeons for VAD, ECMO, and DSC (22/42 [52%]). The majority of respondents indicated that

prophylaxis is continued for the entire duration of VAD placement, ECMO, and DSC procedures
(13/15 [87%], 15/16 [94%], and 24/26 [92%], respectively). Prolonged antimicrobial exposure
not only increases risk of infection with resistant bacteria, but potentially increases the possibility
of fungal infection which can significantly increase mortality risk in patients receiving VAD
support. (8) With technological advances in mechanical circulatory support devices and
improvements in outcomes in children undergoing these procedures, a balance must be made
between adequate antimicrobial prophylaxis duration and selection of antibiotic-resistant
bacteria.
Our survey demonstrated that the use of antimicrobial prophylaxis for congenital heart surgery is
standard. However, there is wide variation in selection and duration of prophylaxis, and areas of
discordance exist between national and organizational recommendations and current practices.
Prolonged use of antimicrobials leads to the increased incidence of resistant enterobacteriaceae
and enterococci. (3, 6) Pharmacists play a critical role in the appropriate use of antimicrobials,
and can seize this opportunity to collaborate with congenital heart surgeons to develop institution
specific protocols for postoperative antibiotic prophylaxis. The development of consensus
recommendations for postoperative antimicrobial prophylaxis for children after cardiac surgery,
and the concurrent design of a national database to collect and assess long-term outcomes
associated with those recommendations may be attainable through pharmacist and surgeon
collaboration.
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